Singh v. Cigna Corp.

17‐3484‐cv
Singh v. Cigna Corp.
In the
United States Court of Appeals
for the Second Circuit
A UGUST TERM 2018
No. 17‐3484‐cv
MINOHOR S INGH ,
Individually and On Behalf of All Others Similarly Situated,
Lead Plaintiff‐Appellant,
v.
C IGNA C ORPORATION, D AVID C ORDANI , THOMAS A. MCC ARTHY ,
H ERBERT A. F RITCH , R ICHARD A PPEL ,
Defendants‐Appellees. *
On Appeal from the United States District Court
for the District of Connecticut
A RGUED: O CTOBER 2, 2018
D ECIDED: MARCH 5, 2019
* The Clerk of Court is directed to amend the caption as set out above.

-- 1 of 14 --

2
Before:
C ABRANES and S ACK, Circuit Judges, and K OELTL, District Judge.†
Lead Plaintiff‐Appellant Minohor Singh, individually and on
behalf of all other similarly situated, (“Plaintiffs”) appeals from an
October 2, 2017 judgment of the United States District Court for the
District of Connecticut (Vanessa L. Bryant, Judge) dismissing this class
action alleging violations of federal securities laws by Cigna
Corporation (“Cigna”) and certain of its officers (jointly,
“Defendants”). Plaintiffs claim that certain of Defendants’ statements
were materially misleading, constituting fraud under Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934 and Securities and
Exchange Commission (“SEC”) Rule 10b‐5. The District Court
determined that the alleged misstatements do not constitute fraud
under the relevant legal standards and granted Defendants’ motion to
dismiss. We conclude that a reasonable investor would not rely on the
challenged statements as representations of regulatory compliance.
Accordingly, we affirm.
D AVID J. G OLDSMITH (James W. Johnson,
Michael H. Rogers, James T. Christie, on the
† Judge John G. Koeltl, of the United States District Court for the Southern
District of New York, sitting by designation.

-- 2 of 14 --

3
brief) Labaton Sucharow LLP, New York,
NY, for Plaintiff‐Appellant.
A NDREW W. S TERN (James O. Heyworth,
Francesca E. Brody, on the brief) Sidley
Austin LLP, New York, NY, for Defendant‐
Appellee.
JOSÉ A. C ABRANES , Circuit Judge:
This case presents us with a creative attempt to recast corporate
mismanagement as securities fraud. The attempt relies on a simple
equation: first, point to banal and vague corporate statements
affirming the importance of regulatory compliance; next, point to
significant regulatory violations; and voila, you have alleged a prima
facie case of securities fraud! The problem with this equation,
however, is that such generic statements do not invite reasonable
reliance. They are not, therefore, materially misleading, and so cannot
form the basis of a fraud case.
Lead‐Plaintiff Minohor Singh, on behalf of himself and other
shareholders, (“Plaintiffs”) appeals from an October 2, 2017 judgment
of the United States District Court for the District of Connecticut
(Vanessa L. Bryant, Judge) dismissing this class action alleging
violations of federal securities laws by Cigna Corporation (“Cigna”)
and certain of its officers (jointly, “Defendants”). Plaintiffs claim that
certain of Defendants’ statements were materially misleading,

-- 3 of 14 --

4
constituting fraud under Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934 and Securities and Exchange Commission
(“SEC”) Rule 10b‐5. The District Court determined that the alleged
misstatements do not constitute fraud under the relevant legal
standards and granted Defendants’ motion to dismiss. We conclude
that a reasonable investor would not rely on the challenged statements
as representations of regulatory compliance. Accordingly, we affirm.
I. BACKGROUND
Cigna’s Acquisition of Healthspring: 1
In early 2012, Cigna, a multi‐national health services 2
organization incorporated in Delaware, purchased HealthSpring Inc., 3
a successful regional Medicare insurer based in Nashville, Tennessee, 4
for $3.8 billion. 1 The goal of the acquisition was to bring Cigna into the 5
fast‐growing Medicare insurance market, complementing Cigna’s 6
commercial health business with Medicare offerings as current Cigna 7
customers aged. Initially, the acquisition appeared to produce 8
benefits: within a year, HealthSpring had become Cigna’s largest 9
source of revenue. 10
Defendants’ Statements Concerning Regulatory Compliance: 11
Cigna’s leadership was aware that HealthSpring’s extensive 12
Medicare business subjected the company to significant regulatory 13
1 Unless otherwise noted, the factual background is drawn from the Second
Amended Complaint, J.A. 74‐160, and the District Court Memorandum of Decision,
SPA 1‐18.

-- 4 of 14 --

5
responsibilities. Indeed, during the acquisition and over the next two 1
years, Cigna and its officers issued several public statements 2
concerning Cigna’s commitment to regulatory compliance. As 3
relevant here, these statements include the following: 4
First, on February 27, 2014, Cigna filed its 2013 Form 10‐K. In a 5
section titled “Regulation,” Cigna claimed to have “established 6
policies and procedures to comply with applicable requirements.”2 7
Similarly, in a section titled “Medicare Regulations,” Cigna asserted 8
that it “expect[s] to continue to allocate significant resources” to 9
various compliance efforts.3 Importantly, the same paragraph also 10
cautioned that Cigna’s Medicare business was “subject to . . . 11
numerous and complex regulations and requirements that are 12
frequently modified and subject to administrative discretion.”4 13
Second, in December 2014, Cigna published a pamphlet titled 14
“Code of Ethics and Principles of Conduct.” The pamphlet includes 15
statements from senior Cigna executives affirming the importance of 16
compliance and integrity. In particular, the pamphlet stated that “it’s 17
so important for every employee . . . to handle, maintain, and report 18
on [Cigna’s financial] information in compliance with all laws and 19
regulations,” and that “we have a responsibility to act with integrity 20
2 J.A. 215.
3 Id. at 218.
4 Id.

-- 5 of 14 --

6
in all we do, including any and all dealings with government 1
officials.” 5 2
Third, on February 26, 2015, Cigna filed its 2014 Form 10‐K. Like 3
the 2013 Form 10‐K, this form states that Cigna “expect[s] to continue 4
to allocate significant resources” to compliance.6 The 2014 form, 5
however, omits the claim that Cigna has “established policies and 6
procedures to comply with applicable requirements.” Additionally, it 7
contains an expanded discussion of the difficulty of compliance given 8
the regulatory uncertainty surrounding legislation and 9
implementation of national healthcare reform.7 10
Cigna’s Regulatory Compliance Challenges: 11
During the period these statements were released, however, 12
Cigna’s Medicare operations experienced a series of compliance 13
failures. 14
Prior to its acquisition by Cigna, HealthSpring had never been 15
sanctioned or cited for non‐compliance by the Centers for Medicare 16
and Medicaid Services (“CMS”), the regulatory body that oversees 17
Medicare services. From April 2014 through December 2015, however, 18
Cigna received more than 75 CMS notices for a variety of compliance 19
infractions. Although Plaintiffs do not specify the severity of each 20
5 Id. at 411, 417.
6 Id. at 200.
7 Id. at 196‐97.

-- 6 of 14 --

7
notice, such notices vary in seriousness from a Notice of Non‐ 1
Compliance” (which CMS describes as its “[m]ildest type of letter . . . 2
not contain[ing] specific language regarding further compliance 3
escalation or other consequences should the behavior/non‐compliance 4
continue”) to the more severe “Corrective Action Plan” (which 5
“indicates continuing and/or severe, systemic problems”).8 6
In October 2015, CMS conducted an extensive audit of Cigna’s 7
Medicare operations. On January 21, 2016, CMS informed Cigna by 8
letter that CMS auditors had concluded that “Cigna substantially 9
failed to comply with CMS requirements” regarding coverage 10
determinations, appeals, benefits administration, compliance program 11
effectiveness and similar matters.9 The letter also notes that “Cigna has 12
had a longstanding history of non‐compliance with CMS 13
requirements” as demonstrated by the receipt of numerous prior 14
notices.10 CMS also informed Cigna that it would impose intermediate 15
sanctions suspending enrollment of Medicare beneficiaries effective at 16
11:59 p.m. that night. The next day, Cigna filed a Form 8‐K disclosing 17
its receipt of the CMS letter and the accompanying sanctions. 18
19
20
8 Id. at 349.
9 Id. at 166.
10 Id.

-- 7 of 14 --

8
Cigna’s Stock Price Drops and Plaintiffs File Suit: 1
Over the next four days, Cigna’s stock price fell substantially, 2
from $140.13 to $135.85.11 3
On February 4, 2016, Cigna investor Jyotindra Patel filed a 4
putative class action against Cigna on behalf of all individuals who 5
had acquired Cigna securities between February 27, 2014 (the date of 6
the 2013 Form 10‐K) and January 21, 2016 (the date of the CMS letter 7
and sanction). 12 On April 4, 2016, Plaintiff‐Appellant Minohor Singh 8
moved for appointment as lead plaintiff, arguing that he (rather than 9
Patel) was the “most adequate” representative due to his “substantial 10
financial interest” and retention of a “nationally recognized securities 11
class action litigation firm.”13 On May 17, 2016 the District Court 12
granted Singh’s motion. 14 13
On July 29, 2016, Cigna announced that it had already spent 14
nearly $30 million to remedy the compliance violations, but that it may 15
“not be able to address matters arising from the [CMS Sanctions] 16
11 Id. at 87.
12 See Singh v. Cigna Corp., No. 3:16‐cv‐182 (VLB), Dkt. No. 1 at 2.
13 See id., Dkt. No. 27‐1 at 1‐2.
14 See id., Dkt. No. 34 at 1.

-- 8 of 14 --

9
Notice in a timely and satisfactory manner.”15 At the close of trading 1
on August 2, 2016, Cigna’s stock price had fallen to $124.13 per share. 2
On August 1, 2016 Plaintiffs (now represented by Lead Plaintiff 3
Singh) filed an amended complaint,16 and on November 30, 2016, 4
Plaintiffs filed a second amended complaint, extending the class 5
period to August 2, 2016.17 On February 13, 2017, Defendants filed a 6
motion to dismiss, and on October 2, 2017, the District Court entered 7
judgement granting the motion. This appeal followed. 8
II. DISCUSSION 9
“We review the grant of a motion to dismiss de novo, accepting 10
as true all factual claims in the complaint and drawing all reasonable 11
inferences in the plaintiff’s favor.”18 To avoid dismissal under Section 12
10(b) and Rule 10b‐5, a complaint must plausibly allege: “(1) a material 13
misrepresentation (or omission); (2) scienter, i.e., a wrongful state of 14
mind; (3) a connection with the purchase or sale of a security; (4) 15
15 J.A. 88. Although the complaint does not provide a citation, the above
quotation appears to be drawn from Cigna’s 10‐Q. See Cigna Second Quarter Form
10‐Q (July 29, 2016), available at https://www.cigna.com/about‐
us/investors/quarterly‐reports‐and‐sec‐filings/. See also, Tellabs, Inc. v. Makor Issues
& Rights, Ltd., 551 U.S. 308, 322 (2007) (“courts ordinarily examine . . . documents
incorporated into the complaint by reference”).
16 See Singh v. Cigna Corp., No. 3:16‐cv‐182 (VLB), Dkt. No. 40.
17 See id., Dkt. No. 57.
18 Fink v. Time Warner Cable, 714 F.3d 739, 740–41 (2d Cir. 2013).

-- 9 of 14 --

10
reliance . . . ; (5) economic loss; and (6) loss causation.” 19 Plaintiffs must 1
allege those facts that give rise to an inference of scienter “with 2
particularity.”20 3
Here, the District Court dismissed the second amended 4
complaint on the grounds that Plaintiffs failed to sufficiently allege 5
both materially false statements and scienter. On appeal, Plaintiffs 6
contest both holdings. Because we agree with the District Court 7
regarding the absence of a material, false statement, we need not reach 8
the issue of scienter. 9
An alleged misrepresentation is material if “there is a 10
substantial likelihood that a reasonable person would consider it 11
important in deciding whether to buy or sell shares of stock.”21 Such a 12
statement must, in the view of a reasonable investor, have 13
“significantly altered the ‘total mix’ of information made available.”22 14
The statement must also be “mislead[ing],” evaluated not only by 15
“literal truth,” but by “context and manner of presentation.”23 16
19 Kleinman v. Elan Corp., plc, 706 F.3d 145, 152 (2d Cir. 2013) (internal
quotation marks and brackets omitted).
20 ATSI Commc’ns, Inc. v. Shaar Fund, Ltd., 493 F.3d 87, 99 (2d Cir. 2007).
21 Operating Local 649 Annuity Tr. Fund v. Smith Barney Fund Mgmt. LLC, 595
F.3d 86, 92–93 (2d Cir. 2010) (internal quotation marks and brackets omitted)
22 ECA, Local 134 IBEW Joint Pension Tr. of Chicago v. JP Morgan Chase Co., 553
F.3d 187, 197 (2d Cir. 2009) (quoting Basic Inc. v. Levinson, 485 U.S. 224, 231‐32
(1988)) (internal quotation mark omitted).
23 Operating Local 649, 595 F.3d at 92 (brackets omitted).

-- 10 of 14 --

11
On appeal, Plaintiffs highlight the three groups of statements 1
discussed above, i.e., the 2013 and 2014 Form 10‐K statements and the 2
2014 Code of Ethics statements. Plaintiffs’ argument that these 3
statements are materially misleading rests on two premises: (1) that a 4
reasonable stockholder would rely on these statements as 5
representations of satisfactory legal compliance by Cigna; and (2) that 6
when the statements were made, Cigna was not, in fact, legally 7
compliant. We reject the first claim. A reasonable stockholder would 8
not “consider [these statements] important in deciding whether to buy 9
or sell shares of stock.”24 They cannot, therefore, constitute “material 10
misstatements.” 11
Like the District Court, we think that the statements in Cigna’s 12
Code of Ethics are a textbook example of “puffery.” We have observed 13
that “general statements about reputation, integrity, and compliance 14
with ethical norms are inactionable ‘puffery,’ meaning that they are 15
too general to cause a reasonable investor to rely upon them.”25 The 16
Code of Ethics statements, which amount to general declarations 17
about the importance of acting lawfully and with integrity, fall 18
squarely within this category. 19
We similarly think that a reasonable investor would not rely on 20
the 2013 and 2014 Form 10‐K statements as representations of 21
24 Id. at 92‐93 (internal quotation marks and brackets omitted).
25 City of Pontiac Policemen’s & Firemen’s Ret. Sys. v. UBS AG, 752 F.3d 173,
183 (2d Cir. 2014) (internal quotation marks omitted).

-- 11 of 14 --

12
satisfactory compliance. In the past, when we have found that 1
descriptions of compliance efforts amounted to actionable assurances 2
of actual compliance, the descriptions of such efforts were far more 3
detailed.26 For example, in Meyer v. Jinkosolar, the case on which 4
Plaintiffs principally rely, we emphasized that the company described 5
its compliance mechanisms in confident detail, including references to 6
24‐hour monitoring teams, specific compliance equipment, and its 7
clean compliance record. We illustrated that detail with a lengthy 8
quotation from the company’s prospectus: 9
We have installed pollution abatement equipment at our 10
facilities to process, reduce, treat, and where feasible, recycle the 11
waste materials before disposal, and we treat the waste water, 12
gaseous and liquid waste and other industrial waste produced 13
during the manufacturing process before discharge. We also 14
maintain environmental teams at each of our manufacturing 15
facilities to monitor waste treatment and ensure that these waste 16
emissions comply with Peopleʹs Republic of China 17
environmental standards. Our environmental teams are on duty 18
24 hours. We are required to comply with all PRC national and 19
local environmental protection laws and regulations and our 20
operations are subject to periodic inspection by national and 21
local environmental protection authorities. PRC national and 22
local environmental laws and regulations impose fees for the 23
discharge of waste materials above prescribed levels, require the 24
payment of fines for serious violations and provide that the 25
relevant authorities may at their own discretion close or 26
suspend the operation of any facility that fails to comply with 27
26 See Meyer v. Jinkosolar Holdings Co., 761 F.3d 245, 251 (2d Cir. 2014).

-- 12 of 14 --

13
orders requiring it to cease or remedy operations causing 1
environmental damage. As of December 31, 2009, no such 2
penalties had been imposed on us.27 3
Such detailed descriptions stand in sharp contrast to Cigna’s simple 4
and generic assertions about having “policies and procedures” and 5
allocating “significant resources.” 6
Moreover, each of Cigna’s statements was framed by 7
acknowledgements of the complexity and numerosity of applicable 8
regulations. 28 Such framing suggests caution (rather than confidence) 9
regarding the extent of Cigna’s compliance. Similarly, Cigna’s 10
assertion that it “expect[s] to continue to allocate significant 11
resources”29 to regulatory compliance suggests a company actively 12
working to improve its compliance efforts, rather than one expressing 13
confidence in their complete (or even substantial) effectiveness. If 14
anything, these statements seem to reflect Cigna’s uncertainty as to the 15
very possibility of maintaining adequate compliance mechanism in 16
light of complex and shifting government regulations.30 17
27 Id. at 247‐48 (emphasis and brackets omitted).
28 J.A. 196‐97, 214.
29 Id. at 200, 218 (emphasis added).
30 See id. at 197. Variations between the 2013 and 2014 10‐K forms,
particularly the omission in 2014 of Cigna’s previous statement that it had
“established policies and procedures,” do not change our analysis. First, this
statement, like the rest of the of the statements at issue, was couched in tentative
terms. Moreover, the totality of the “Regulation” sections in the 2013 and 2014
forms suggests that the variations in language between 2013 and 2014 are likely the

-- 13 of 14 --

14
III. CONCLUSION 1
Because the challenged statements are tentative and generic, 2
and because they emphasize the complex, evolving regulatory 3
environment that Cigna faced, we conclude that Plaintiffs have failed 4
to plausibly allege that a reasonable investor would view these 5
statements “as having significantly altered the total mix of information 6
made available.”31 These statements are not, therefore, materially 7
misleading. 32 8
The October 2, 2017 judgment of the District Court is therefore 9
AFFIRMED. 10
result of increased concern over the unsettled regulatory environment, including
legal challenges to the formidably complex Affordable Care Act, see generally King
v. Burwell, 135 S. Ct. 2480, 2492 (2015), and changes and delays in its
implementation.
31 ECA, 553 F.3d at 197 (internal quotation marks omitted).
32 We also briefly address Plaintiffs’ argument that “notwithstanding the
automatic stay of discovery under the PSLRA,” the District Court “had the
misimpression that Plaintiffs had been receiving the benefit of formal discovery.”
Reply Br. Appellant at 26. A review of the record indicates that Plaintiffs are correct
on this point. In its September 28, 2017 opinion, the District Court repeatedly asserts
that Plaintiffs conducted extensive discovery. Singh v. Cigna Corp., 277 F. Supp. 3d
291, 325 (D. Conn. 2017). However, the District Court’s misimpression on this issue
had no bearing on its decision to dismiss (nor do Plaintiffs so suggest). And while
this misimpression might have some bearing on the District Court’s decision to
deny Plaintiffs leave to amend, see id. at 326, Plaintiffs failed to challenge that
decision on appeal. As “[i]ssues not sufficiently argued in the briefs are considered
waived and normally will not be addressed on appeal,” Norton v. Sam’s Club, 145
F.3d 114, 117 (2d Cir. 1998), we decline to review the District Court’s denial of
further leave to amend the complaint.

-- 14 of 14 --